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ABSTRACT
Objective: To evaluate the performance of QuantiFERON-TB GOLD (QFTG) in a 
resource-poor setting among patients with and without HIV infection. 
Design: Cross-sectional study. 
Setting: Two hospitals in Northern Tanzania.
Subjects: Eighty three adult male and female inpatients. 
Intervention: All patients were screened for HIV infection and underwent tuberculin 
skin test (TST) and QFTG. 
Results: Eighty-three subjects were enrolled, and 29 (35%) of 83 were HIV-infected. 
QFTG yielded indeterminate results in 12 (22%; 95%CI 12%-34%) of 54 HIV-uninfected 
and 13 (45%; 95%CI 26%-64%) of 29 HIV-infected subjects (p=0.0323). Among those 
with smear-positive pulmonary tuberculosis, TST was positive in 40 (100%; 95%CI 
91%-100%) of 40 HIV-uninfected subjects compared with seven (54%; 95%CI 25%-
81%) of 13 HIV-infected subjects (p<0.0001), and QFTG was positive in 28(70%; 95%CI 
53%-83%) of 40 HIV-uninfected subjects compared with three (23%; 95%CI 5%-54%) 
of 13 HIV-infected subjects (p=0.0029). Among medical inpatients at risk for latent 
tuberculosis infection, TST was positive in seven (50%) of 14 HIV-uninfected patients 
and three (19%) of 16 HIV-infected patients (p=0.0701) and QFTG was positive among 
two (14%) of 14 HIV-uninfected patients and three (19%) of 16 HIV-infected patients 
(p=0.7437). 
Conclusions: The presence of HIV co-infection was associated with a significant reduction 
in sensitivity of both the TST (p<0.0001) and QFTG (p=0.0029) for the diagnosis of 
active M.tuberculosis infection. The high proportion of indeterminate QFTG and lack 
of sensitivity, particularly among HIV-infected patients, may limit its applicability in 
settings like Tanzania. Larger studies in resource-poor settings are required.
INTRODUCTION
Tuberculosis is a leading killer of HIV-infected 
Africans and accounts for about a third of AIDS 
deaths worldwide. HIV-infected patients will develop 
active TB at a higher rate than those who are not 
infected with HIV(1) and nosocomial transmission 
of drug-resistant tuberculosis has been shown to 
be a major source of mortality among HIV-infected 
patients in South Africa (2). Therefore, diagnosis 
and treatment of latent tuberculosis infection (LTBI) 
is critical among hospitalised patients in endemic 
areas. Tuberculin skin testing (TST), the current 
standard of care for diagnosing latent tuberculosis 
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infection, reflects technology from the early part of 
the 20th century and is plagued by several limitations 
including poor specificity, limited sensitivity, the need 
for a return visit to perform skin test reading, and 
variability inherent in its application and reading (3). 
Furthermore, these limitations are magnified in the 
immunosuppressed host. Malnutrition alone causes 
false negative results and HIV-infected subjects have 
significantly depressed delayed type hypersensitivity 
responses resulting in up to 50% of co-infected persons 
testing “negative” with TST, whether 5mm or 10mm 
threshold is used (4).
 Recently, assays that measure IFN-γ cytokine 
production in response to in vitro stimulation of 
lymphocytes with M. tuberculosis derived antigen 
(5, 6) have been developed. QuantiFERON-TB 
GOLD (QFTG; Cellestis Inc, Carnegie, Australia) 
is a commercially available whole blood assay that 
measures IFN-γ response to stimulation with ESAT-6 
and CFP-10, peptides specific for M. tuberculosis. It was 
approved by the U.S. Food and Drug Administration 
in 2004 for the diagnosis of latent tuberculosis infection 
and has demonstrated increased specificity in bacille 
Calmette-Guérin (BCG) vaccine recipients compared 
to TST. Because of the lack of a gold standard for 
the diagnosis of LTBI, sensitivity of QFTG has been 
assessed based on detection of patients with active 
tuberculosis (7). However, limited data exist regarding 
its use in HIV-infected patients (8, 9) and in resource-
poor settings (10, 11). Furthermore, there are no 
published studies on the use of QFTG in hospitalised 
patients in countries where TB is endemic. 
 Since HIV co-infection represents the greatest 
risk factor for development of active tuberculosis 
and reduces the sensitivity of diagnostic methods 
used routinely in resource-poor settings, we sought 
to evaluate the utility of QFTG in Tanzania, a country 
with high prevalence of both M. tuberculosis and 
HIV infection as well as a national standard of BCG 
vaccination. Our study was designed to answer 
two questions. First, what are the performance 
characteristics among general inpatients at risk for 
latent tuberculosis infection (LTBI) in a country where 
the incidence of TB is high (347/100,000 person/year) 
and HIV co-infection (36%) is common (12). Second, 
what is the sensitivity of QFTG among HIV-infected 
hospitalised patients using smear positive pulmonary 
TB as a diagnostic gold standard?.
MATERIALS AND METHODS
Study participants: All subjects were recruited from two 
hospitals in northern Tanzania: Kilimanjaro Christian 
Medical Centre (KCMC) and Kibong’oto National 
Tuberculosis Hospital (KNTH) between March and 
May, 2004. Subjects at KCMC were screened for 
entry based on age > 18 years, expected inpatient 
status > 48 hours, and referral by their primary team 
for inpatient HIV voluntary counseling and testing 
(VCT). Subjects at KNTH were screened for entry 
based on age > 18 years, first diagnosis of smear 
positive pulmonary TB, and treatment duration 
less than 42 days. Written informed consent was 
obtained from all subjects or their next of kin. KCMC 
subjects were asked about risk factors for exposure 
to TB including known household contact (defined 
as living with someone with active tuberculosis), 
presence and duration of cough, and previous or 
current treatment for TB. Chest radiograph (CXR) 
results within three months of presentation were 
solicited from the medical record, if not obtained on 
admission. CXR were reviewed by a single attending 
radiologist and assessed for the number of abnormal 
segments (0-6). All subjects were assessed for the 
presence of BCG vaccination scar over the deltoid. 
Information on semi-quantitative AFB smear results 
of KNTH subjects was obtained from their current 
medical record. Patients were subgrouped into TB 
Patients (those with documented smear positive 
pulmonary tuberculosis) and LTBI/BCG Patients 
(medical inpatients at risk for latent tuberculosis 
infection and history of BCG vaccination).
 Sample collection and TST: A heparinised blood 
sample (5-10ml) was collected by venipuncture, stored 
at room temperature, and processed for QFTG within 
twelve hours. Blood was collected prior to placement 
of tuberculin skin test (TST) by the Mantoux method. 
Briefly, 0.1ml (5TU) Tubersol reagent (Connaught 
Laboratories Inc, Toronto, Ontario) was injected 
intradermally into the volar aspect of the forearm 
and transverse/longitudinal induration diameter was 
measured 48-72 hours later by a principal investigator. 
For all subjects, a positive TST was defined as ≥ 10mm 
unless the subject was HIV-infected, then the cutoff 
was ≥ 5mm. 
 Whole blood IFN-γ assay: The whole blood IFN-γ 
assay, QuantiFERON-TB GOLD [QFTG] (Cellestis 
Inc., Carnegie, Australia) was used. The recently 
updated QFTG ‘in-tube’ was not available at the time. 
Assays were performed according to manufacturer’s 
instructions except that IFN-γ standards were 
measured in duplicate at 1:1 (8 IU/ml), 1:3, 1:9, 1:27, 
1:81, and Nil concentrations on each plate as opposed 
to 1:1 (4 IU/ml), 1:4, 1:16, and Nil as recommended 
by the manufacturer. This was done because the 
correlation coefficient of the standard curve was not 
consistently robust, and we had a limited amount 
of IFN-γ standard with which to troubleshoot in 
the field. Importantly, all predefined quality control 
measures were met for each patient sample. ELISA 
plates were read with Dynex MRX II and associated 
Dynex Revelation software (Chantilly, VA) was used 
to interpolate IFN-γ concentrations from optical 
density measurements.
 HIV testing: Prior to HIV testing, all subjects 
underwent appropriate pretest counseling provided 
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by the local nursing staff. For subjects at KCMC, 
testing was performed using serum samples obtained 
after stimulation with Nil antigen and subsequent 
freezing at –80oC. Samples were brought to room 
temperature, vortexed, and then tested. For subjects at 
KNTH, testing was performed on whole heparinised 
blood. 
 In both groups, rapid agglutination assays using 
World Health Organisation (WHO) recommended 
protocol were applied. All samples first underwent 
Determine HIV1/2 (Abbott Labs, Germany). If 
indeterminate or positive, confirmatory testing was 
done with Capillus HIV-1/HIV-2 (Trinity Biotech, 
Ireland). Subjects at KCMC also had their blood 
tested in the hospital clinical laboratory by ELISA 
(Biomerieux, Netherlands). All subjects received 
the results of their tests and underwent post-test 
counseling. 
 Statistical analysis: Data were entered using 
Microsoft Excel (Microsoft Inc., Redmond, WA) and 
analysed using Stata version 9.2 (Stata Corporation, 
College Station, TX). Differences in proportions 
were analysed using two-sample proportions 
tests for binomial probabilities; differences in the 
distribution of continuous variables were analysed 
using Wilcoxon’s rank sum test. Odds ratios for 
differences in proportions and sensitivities, and their 
95% confidence intervals, were calculated using the 
Koopman method (13). Significance was evaluated 
at p=0.05 using two-sided tests. Based on 87% 
sensitivity of QFTG in healthy patients according 
to the manufacturer, we estimated a sample size of 
100 would allow us to detect a clinically significant 
change of at least 7-10%.
Ethics: The research protocol was approved by an 
Institutional Review Board of Duke University 
Medical Centre, the Kilimanjaro Christian Medical 
Centre Research Ethics Committee, and the Tanzania 
National Institute of Medical Research Coordinating 
Committee. 
RESULTS
We approached 100 patients and enrolled 83 in our 
study (Table 1). Fourty seven (57%) of 83 enrolled 
patients were male and the median age was 36 years 
(range 20 – 73 years). Patients were subgrouped 
into TB Patients (those with documented smear 
positive pulmonary tuberculosis; n=53) and LTBI/
BCG Patients (medical inpatients at risk for latent 
tuberculosis infection and history of BCG vaccination; 
n=30). Proportions of TB patients (n=53) and LTBI/
BCG Patients (n=30) with HIV infection (Figure 1). 
Table 1
Clinical characteristics of study subjects stratified by tuberculosis diagnosis
  TB Patients (n=53) LTBI/BCG Patients (n=30) P-value
 No.     (%) No.     (%) 
  
Age in years: mean (sd) 40      16.34 36.9     8.45 0.8052b
Female no. (%) 16     30.2 20      66.7 0.0013a
HIV-infected no. (%) 13     24.5 16      53.3 0.0082a
 BCG scar present no. (%) 41     77.4   28      93.1   0.1505a
Duration of treatment in days (sd) 24.2   14.7 n/a 
 LTBI/BCG Patients  HIV-infected HIV-negative  P-value
No.  16 14   
Household TB contact (%)  21 19 0.8548a
Median duration of cough in days 
(range 0-720)  37 0 0.0314b
Median abnormal segments on chest 
radiography (range 0-6)  2 0 0.1663b
(a) Two-sample binomial proportions test. 
(b) Wilcoxon rank-sums    
* Four patients without chest radiographs were excluded from the calculations  
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Figure 1
Patient enrollment and stratification
TB Patients had documented smear positive 
pulmonary tuberculosis as demonstrated by two 
(2/53) or three (51/53) semi-quantitative AFB 
smears. Subjects received a standard regimen of four-
drug antituberculous therapy (isoniazid, rifampin, 
ethambutol, and pyrazinamide) for a median of 
26 days (IQR 11-39), and this duration of therapy 
did not differ by HIV serostatus (p=0.9669). The 
remainder of enrolled patients (LTBI/BCG Patients) 
were more often female and had a higher incidence 
of HIV-infection than TB Patients. Analyses of 
epidemiologic, clinical, and radiographic findings 
from LTBI/BCG patients are listed in Table 1, 
stratified by HIV serostatus. Only the median 
duration of cough was significantly different; higher 
among HIV-infected patients. Most often, LTBI/BCG 
Patients were hospitalised for reasons unrelated to 
tuberculosis and did not routinely undergo sputum 
testing.       
 Among all patients, TST was positive among 47 
(87%; 95%CI 75%-95%) of 54 HIV-uninfected patients 
and 10 (35%; 95%CI 18%-54%) of 29 HIV-infected 
patients (OR= 2.52; 95%CI 1.62- 4.40; p<0.0001). QFTG 
was positive among 30 (56%; 95CI 41%-69%) of 54 
HIV-uninfected patients and 6(21%; 95%CI 8%-40%) of 
29 HIV-infected patients (OR= 2.68; 95%CI 1.37-5.82; 
p=0.0022). QFTG yielded indeterminate results in 
12 (22%; 95%CI 12%-34%) of 54 HIV-uninfected and 
13(45%; 95%CI 26%-64%) of 29 HIV-infected subjects 
(p = 0.0323) (Figure 2). 
100 patients screened
 10 (10%) refused consent
 7 (7%) excluded
 3 insufficient blood
 4 QFTG Technical error
83 (83%) patients enrolled
53 (64%) smear 
positive pulmonary 
tuberculosis
30 (36%) medical 










TB Patients LTBI/BCG Patients
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Figure 2
Performance of QFTG and TST among all patients
Among LTBI/BCG Patients, TST was positive among 
seven (50%) of 14 HIV-uninfected patients and three 
(19%) of 16 HIV-infected patients (p=0.0701). QFTG 
was positive among two (14%) of 14 HIV-uninfected 
and three (19%) of 16 HIV-infected patients (p=0.7437) 
(Figure 3). Indeterminate QFTG responses were noted 
in 12(40%) of 30 patients in this group. 
 Among TB Patients, TST was positive in 40 (100%; 
95%CI 91%-100%) of 40 HIV-uninfected subjects 
compared with seven (54%; 95%CI 25%-81%) of 13 
HIV-infected subjects (OR=1.86; 95%CI 1.28- 3.39; 
p<0.0001), and QFTG was positive in 28(70%; 95%CI 
53%-83%) of 40 HIV-uninfected subjects compared 
to three (23%; 95%CI 5%-54%) of 13 HIV-infected 
subjects (OR=3.03; 95%CI 1.34-8.69; p=0.0029) (Figure 
4). QFTG was less sensitive than TST in detecting 
subjects with smear positive pulmonary tuberculosis 
among HIV-uninfected (OR=0.7; 95%CI 0.55-0.84; 
p=0.0002) but not in HIV-infected (OR=0.43; 95%CI 
0.14-1.18; p=0.1069) subjects. When restricting our 
analysis to patients with smear positive pulmonary 
tuberculosis and a treatment duration of 14 days 
or less, QFTG was positive among 13(72%) of 18 
patients, with 11(84%; 95%CI 55%-98%) of 13 HIV-
uninfected patients and two (40%; 95%CI 5%-85%) of 
five HIV-infected patients (OR=2.11; 95%CI 0.98-7.30; 
p=0.0583) having positive QFTG results.  QFTG and 
TST showed modest agreement among all subjects 
(67.47%) (Table 2). 
Figure 3
Performance of QFTG and TST among medical           
in-patients at risk for tuberculosis
Figure 4
Performance of QFTG and TST in -patients with smear 
positive pulmonary tuberculosis
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Table 2
 Agreement between QFTG and TST among all HIV-
infected and uninfected subjects
            HIV-               HIV-              All 
            seronegative         seropositive           Subjects
 QFTG QFTG  QFTG QFTG  QFTG QFTG 
  (+) (-)  (+) (-)  (+) (-)
TST (+) 29 8 4 3 33 12
TST (-) 1 4 2 7 3 12
% agree        64.81%                   72.41%               67.47%
Kappa           0.364                     0.355             0.448
p-value         0.003                    0.076           <0.001
Most often, results were concordant (53%) or QFTG 
result was indeterminate (30%). QFTG was negative 
in eight smear positive subjects (six HIV-uninfected 
and two HIV-infected), and indeterminate in nine 
additional subjects (six HIV-uninfected and three 
HIV-infected). In only one subject did QFTG detect 
pulmonary TB when TST was falsely negative. 
DISCUSSION
We demonstrate that QFTG is less sensitive than TST 
in detecting pulmonary tuberculosis in both HIV-
infected and HIV-uninfected hospitalised patients 
in Tanzania. We also demonstrate a high proportion 
of indeterminate QFTG results among both HIV-
infected (45%) and HIV-uninfected (22%) patients. 
In contrast to published studies, we present the 
results of implementing QFTG in a country with high 
prevalence of tuberculosis where hospitalised patients 
were systematically screened for the presence of HIV 
co-infection. The large number of indeterminate 
QFTG even among HIV-uninfected hospitalised 
patients has immediate implications for the use of 
QFTG as a screening tool in the resource-limited 
nosocomial setting. 
 HIV co-infection markedly reduced the sensitivity 
of TST and QFTG to detect smear positive pulmonary 
tuberculosis by 46% (p<0.0001) and 67% (p=0.0029) 
respectively. The large number of QFTG indeterminate 
responses were the result of sub-threshold responses 
to a positive control antigen (phytohemagglutinin), 
suggestive of global immunosuppression. A recently 
published study conducted in South Africa noted 
indeterminate QFTG results in five (7%) of 74 
HIV-infected and two (2%) of 84 HIV-uninfected 
subjects (14). However, this study was conducted 
in ambulatory (not hospitalised) patients and the 
median CD4 count of HIV-infected participants was 
392/mm3. Indeterminate responses were more likely 
if CD4 < 100/mm3, which has been noted previously 
(8). Unpublished data from Kibong’oto National 
Tuberculosis Hospital in Tanzania reveal a median 
CD4 count of 104 cells/mm3 in HIV-infected patients 
with tuberculosis (15), suggesting our patients were 
more immunocompromised than those in published 
studies. In another study from South Africa, 23(15%) 
of 154 patients with culture-confirmed pulmonary 
tuberculosis had indeterminate QFTG results, but they 
were not systematically screened for the presence of 
HIV co-infection (11). CD4 counts are not routinely 
available in resource-poor settings such as ours, 
though this information could help stratify those for 
whom QFTG would be appropriate. 
 According to the manufacturer, the overall 
sensitivity of QFTG is 87.6% in culture-confirmed 
pulmonary tuberculosis. In Tanzania, mycobacterial 
culture facilities are not routinely available, so we 
included patients with acid fast bacilli on sputum 
microscopy and a clinical picture consistent with 
tuberculosis, criteria which would merit treatment 
under the National Tuberculosis Programme. Only 
70% of HIV-uninfected subjects with smear positive 
pulmonary tuberculosis had positive QFTG results in 
our study, and a number of factors could contribute to 
this reduced sensitivity. First, it is possible that some 
of the HIV-uninfected patients were infected with 
non-tuberculous mycobacteria (NTM), resulting in 
a falsely reduced sensitivity of QFTG. However, the 
predictive value of expectorated sputum microscopy 
for diagnosis of pulmonary tuberculosis is high even 
in settings where NTM are prevalent (16). Second, the 
median duration of antituberculous therapy in our 
cohort was 26 days, and prolonged treatment duration 
has been suggested to increase TST but reduce IFN-
γ responses. In fact, we observed 100% sensitivity 
of TST compared to 70% with QFTG (p=0.0002). 
Among patients with smear positive pulmonary 
tuberculosis who received treatment less than 14 days, 
we did not observe a difference in the rate of QFTG 
positivity (p=0.0583) by HIV status; however, our 
sample size was not large enough to determine the 
effect of duration of tuberculosis therapy on QFTG 
performance. In a recent longitudinal study of the 
effect of LTBI treatment, it was noted that antigen 
specific T-cell responses increased 1.8 fold, peaking at 
26 days before decreasing by the end of the treatment 
period (14). Additionally, health care workers in 
India treated for LTBI demonstrated positive QFTG 
results up to ten months after completing a course 
of treatment (17). Thus, while treatment duration 
may explain the discordance in sensitivity of QFTG 
relative to TST in HIV-uninfected patients, it is not 
clear that it would necessarily decrease the absolute 
sensitivity. Third, the nutritional status of the subjects, 
concomitant medical illness, and the presence of 
active TB itself, which has been shown to abrogate 
IFN-γ cytokine responses (18), may have had an 
effect. Finally, we do not believe that deviation from 
manufacturer’s recommendations in analysing IFN-γ 
standards affected the sensitivity of the assay since 
all predefined quality control criteria were met.
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 We noted a statistically significant difference in 
the proportion of HIV-infected patients among the 
two groups recruited from different hospitals which 
reflects the referral bias to a national tuberculosis 
hospital (KNTH) and local referral hospital (KCMC). 
Since KCMC is a referral hospital whose patients 
carry a very high level of acuity, the presence of 
malnutrition was a major confounding variable 
and additional clinical information such as body 
mass index or admitting diagnoses could have 
helped further stratify TB risk in this group. The 
characteristics of enrolled patients were not suitable 
to assessing specificity of QFTG, and this was not one 
of our stated objectives since high specificity has been 
previously demonstrated in healthy BCG-vaccinated 
subjects (7). However, we observed modest agreement 
(64.81%; κ=0.364; p=0.003) between TST and QFTG 
among HIV-uninfected patients despite routine 
BCG vaccination and possible infection with non-
tuberculous mycobacteria. A competing technology, 
the T-SPOT.TB (Oxford Immunotech, Oxford, UK) 
ELISPOT assay, appears to have a high sensitivity for 
identifying M. tuberculosis infection in HIV co-infected 
patients (19, 20), and direct comparison with QFTG 
suggests moderate agreement (κ=0.37) between the 
tests(10). 
 Our experience demonstrates that QFTG 
can be successfully performed in resource-poor 
settings; however, the technical training required is 
multifaceted and includes proper venipuncture and 
tissue culture technique, performance and reading 
of ELISA plates, and complex quality control and 
data analysis. Routine use of QFTG among medical 
inpatients at risk for LTBI yielded a large number of 
indeterminate results, and the sensitivity of QFTG was 
markedly reduced by the presence of HIV co-infection. 
Despite the best of circumstances, the reduced 
sensitivity of QFTG observed in this report highlights 
the limitations of any immunologically based assay: 
reliance on an intact immunologic response in the 
setting of acute disease or concomitant illness in 
order to give positive results. That assumption is 
particularly problematic in the background of HIV 
infection, malnutrition, and other co-infections 
common in developing world contexts where TB is 
endemic. The results of this investigation should be 
confirmed by larger studies in hospitals in resource-
poor settings.
ACKNOWLEDGEMENTS
To Dr. John F. Shao for his administrative assistance, 
Dr. Chris Drakeley for technical assistance, and the 
nursing and administrative staff at KCMC and KNTH 
without whom this work would have been impossible. 
This work was presented in part at 3nd International 
AIDS Society Conference on HIV Pathogenesis and 
Treatment, Rio de Janiero, Brazil, July 24-27, 2005. 
Abstract TuPe7.1C09.
Grant Support: Drs. Bartlett and Thielman are 
supported by the AIDS Clinical Trials Group (U01-
AI39156), and Dr. Bartlett by a Mid-Career Investigator 
Award (K24-AI0174). Dr. Seshadri was supported by 
amfAR Travel Grant (#106470-34-RGGN) for the 
duration of this study. Dr. Asmuth is supported by 
NIH R01AI051999-03. 
Conflict of Interest Statement: All authors state no 
conflict of interest. 
REFERENCES
1. Nunn, P., Williams, B., Floyd, K., et al. Tuberculosis 
control in the era of HIV. Nat. Rev. Immunol. 2005;5: 
819-826.
2. Gandhi, N.R., Moll, A., Sturm, A.W.,  et al. Extensively 
drug-resistant tuberculosis as a cause of death in 
patients co-infected with tuberculosis and HIV in 
a rural area of South Africa. Lancet 2006; 368: 1575-
1580.
3. Lee, E. and Holzman, R.S. Evolution and current 
use of the tuberculin test. Clin. Infect. Dis. 2002; 34: 
365-370.
4. Markowitz, N., Hansen, N.I., Wilcosky, T.C., et al. 
Tuberculin and anergy testing in HIV-seropositive and 
HIV-seronegative persons. Pulmonary Complications 
of HIV Infection Study Group. Ann. Intern. Med. 1993; 
119: 185-193.
5. Lalvani, A., Pathan, A.A., McShane, H., et al. Rapid 
detection of Mycobacterium tuberculosis infection by 
enumeration of antigen-specific T cells. Am. J. Respir. 
Crit. Care Med. 2001;163: 824-828.
6. Streeton, J.A., Desem, N. And Jones, S.L. Sensitivity 
and specificity of a gamma interferon blood test for 
tuberculosis infection. Int. J. Tuberc. Lung Dis. 1998; 
2: 443-450.
7. Mori, T., Sakatani, M., Yamagishi, F.,  et al. Specific 
detection of tuberculosis infection: an interferon-
gamma-based assay using new antigens. Am. J. Respir. 
Crit. Care Med. 2004;170: 59-64.
8. Brock, I., Ruhwald, M., Lundgren, B., et al. Latent 
tuberculosis in HIV positive, diagnosed by the M. 
tuberculosis specific interferon-gamma test. Respir. 
Res. 2006; 7: 56.
9. Luetkemeyer, A.F., Charlebois, E.D., Flores, L.L., 
et al. Comparison of an interferon-gamma release 
assay with tuberculin skin testing in HIV-infected 
individuals. Am. J. Respir. Crit. Care Med. 2007;175: 
737-742.
10. Rangaka, M.X., Wilkinson, K.A., Seldon, R., et al. 
Effect of HIV-1 infection on T-Cell-based and skin 
test detection of tuberculosis infection. Am. J. Respir. 
Crit. Care Med. 2007; 175: 514-520.
11. Tsiouris, S.J., Coetzee, D., Toro, P.L., et al. Sensitivity 
analysis and potential uses of a novel gamma 
interferon release assay for diagnosis of tuberculosis. 
J. Clin. Microbiol. 2006; 44: 2844-2850.
12. WHO. Country Profile: United Republic of Tanzania; 
2006.
September 2008 EAST AFRICAN MEDICAL JOURNAL   449
13. Wang, D. sg 154: Confidence intervals for the ratio 
of two binomial proportions by Koopman’s Method. 
Stata. Technical Bulletin. 2000;16-19.
14. Wilkinson, K.A., Kon, O.M., Newton, S.M.,  et al. Effect 
of treatment of latent tuberculosis infection on the T 
cell response to Mycobacterium tuberculosis antigens. 
J. Infect. Dis. 2006; 193: 354-359.
15. Shao, H.J., Crump, J.A., Ramadhani, H.O., et al. A 
randomized trial of early vs. delayed fixed dose 
combination Zidovudine/ Lamivudine/ Abacavir 
in patients co-infected with HIV and tuberculosis: 
Early findings of the tuberculosis and HIV immune 
reconstitution syndrome trial (THIRST). In: 13th 
conference on retroviruses and opportunistic 
infections; 2006; Denver, Colorado; 2006.
16. Yajko, D.M., Nassos, P.S., Sanders, C.A., et al. 
High predictive value of the acid-fast smear for 
Mycobacterium tuberculosis despite the high 
prevalence of Mycobacterium avium complex in 
respiratory specimens. Clin. Infect. Dis. 1994; 19: 
334-336.
17. Pai, M., Joshi, R., Dogra, S., et al. Persistently elevated 
T cell interferon-gamma responses after treatment 
for latent tuberculosis infection among health care 
workers in India: a preliminary report. J. Occup. Med. 
Toxicol. 2006; 1: 7.
18. Zhang, M., Lin, Y., Iyer, D.V., et al. T-cell cytokine 
responses in human infection with Mycobacterium 
tuberculosis. Infect. Immun. 1995; 63: 3231-3234.
19. Liebeschuetz, S., Bamber, S., Ewer, K., et al. Diagnosis 
of tuberculosis in South African children with a T-
cell-based assay: a prospective cohort study. Lancet. 
2004; 364: 2196-2203.
20. Dheda, K., Lalvani, A., Miller, R.F., et al. Performance 
of a T-cell-based diagnostic test for tuberculosis 
infection in HIV-infected individuals is independent 
of CD4 cell count. Aids. 2005;19: 2038-2041.
